24 Jan 2019 --- Global biotechnology company Novozymes has announced “a satisfactory 2018 performance,” which was in line with its initial outlook. The Danish firm has pegged its 2019 guidance of 3-6 percent organic sales growth and 28-29 percent EBIT margin. The company also highlighted organic sales growth of +4 percent (Q4: +2 percent) in 2018 and -1 percent in DKK (Q4: +1 percent). The company also reports that it was a “solid year” for its food and beverage categories with full-year sales growing by 5 percent.
